Drug Profile
PF 6815345
Alternative Names: PF 06815345Latest Information Update: 16 Feb 2017
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 01 Nov 2016 Discontinued - Phase-I for Hypercholesterolaemia (In volunteers) in Belgium (PO) (Pfizer pipeline, February 2017)
- 01 Nov 2015 Phase-I clinical trials in Hypercholesterolaemia (In volunteers) in Belgium (PO) (NCT02654899)